Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candi-date Malaria Vaccine (SB257049) Evaluating Schedules With or With-out Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs GSK 257049 (Primary)
- Indications Falciparum malaria
- Focus Proof of concept; Therapeutic Use
- Acronyms MALARIA-094
- Sponsors GlaxoSmithKline
- 24 Oct 2017 Planned End Date changed from 14 Feb 2022 to 25 Nov 2022.
- 24 Oct 2017 Planned primary completion date changed from 15 Jan 2020 to 15 Apr 2020.
- 24 Oct 2017 Status changed from not yet recruiting to recruiting.